Bandaríkin - enska - NLM (National Library of Medicine)

aspen veterinary resources, ltd. - clomipramine hydrochloride (unii: 2lxw0l6gwj) (clomipramine - unii:nuv44l116d) - calmera is to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age. inappropriate barking or destructive behavior, as well as inappropriate elimination (urination or defecation) may be alleviated by the use of calmera in conjunction with behavior modification. separation anxiety is a complex behavior disorder displayed when the owner (or other attachment figure) leaves the dog. the signs of separation anxiety evaluated in controlled trials were vocalization, destructive behavior, excessive salivation, and inappropriate elimination. in the absence of the owner or attachment figure, dogs with separation anxiety may exhibit one or more of these clinical signs. although the owner (attachment figure) may inadvertently misinterpret this behavior, which only happens in their absence, as spiteful, it is thought to be the result of anxiety experienced by the dog. punishment is not considered appropriate for a dog with separation anxiety. proper recognition of clinical signs, including a complete patient history and assessment of the patient’s household environment, is essential to accurately diagnose and treat separation anxiety. the use of calmera should not replace appropriate behavioral and environmental management but should be used to facilitate a comprehensive behavior management program. calmera is contraindicated in dogs with known hypersensitivity to clomipramine or other tricyclic antidepressants. calmera should not be used in male breeding dogs. testicular hypoplasia was seen in dogs treated for 1 year at 12.5 times the maximum daily dose. calmera should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g. selegiline hydrochloride (l-deprenyl),amitraz]. calmera is contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold. use with caution in dogs with cardiovascular disease. at 20 mg/kg/day (5x the maximum recommended dose), bradycardia and arrhythmias (atrioventricular node block and ventricular extrasystole) were observed in dogs. because of its anticholinergic properties, clomipramine should be used with caution in patients with increased intraocular pressure, a history of narrow angle glaucoma, urinary retention or reduced gastrointestinal motility. because clomipramine is principally metabolized in the liver, caution is advised in using this medication in the presence of preexisting liver disease. calmera is to be used as part of a comprehensive behavioral management program to treat separation anxiety in dogs greater than 6 months of age. inappropriate barking or destructive behavior, as well as inappropriate elimination of (urination or defecation) may be alleviated by the use of calmera in conjunction with behavior modification. separation anxiety is a complex behavior disorder displayed when the owner (or other attachment figure) leaves the dog. in the absence of the owner or attachment figure, dogs with separation anxiety may exhibit one or more clinical signs. the signs of separation anxiety evaluated in controlled trials were vocalization, destructive behavior, excessive salivation, and inappropriate elimination. although it may appear that this behavior, which only happens in the dog owner’s absence, is a spiteful action, this behavior is thought to be a result of anxiety experienced by the dog. therefore, punishment would not be appropriate for the dog with this behavior. calmera is contraindicated in dogs with known hypersensitivity to clomipramine or related tricyclic antidepressants. calmera should not be used in male breeding dogs. testicular hypoplasia was seen in dogs treated for 1 year at 12.5 times the maximum daily dose. calmera should not be given in combination, or within 14 days before or after treatment with a monoamine oxidase inhibitor [e.g. selegiline hydrochloride (l-deprenyl), amitraz]. calmera is contraindicated for use in dogs with a history of seizures or concomitantly with drugs which lower the seizure threshold.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - ciprofloxacin, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: lactic acid; glucose monohydrate; water for injections - aspen ciprofloxacin injection for intravenous infusion is indicated for use in the following. hospitalised adult patients in whom oral ciprofloxacin is indicated but cannot be administered or where the oral form is inappropriate. for the treatment of serious or life-threatening infections due to sensitive organisms involving the following organ systems. lower respiratory tract infections (gram-negative organisms), skin and skin structure, septicaemia, bone and joint, urinary tract. inhalational anthrax (post exposure): to reduce the incidence or progression of disease following exposure to aerosolized bacillus anthracis. ciprofloxacin serum concentrations achieved in humans serve as a surrogate endpoint reasonably likely to predict clinical benefit and provide the basis for this indication. note. because gram-positive organisms are generally less sensitive to ciprofloxacin, it may not be the drug of choice in cases with gram-positive infections, such as pneumonia due to streptococcus pneumoniae. if anaerobic organisms are suspected of contributing to the infection, use of other suitable drugs should be considered. strains neisseria gonorrhoea resistant to ciprofloxacin have been reported in australia. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. ciprofloxacin is suitable to treat mixed infections caused by susceptible strains of both gram-negative and gram-positive aerobic bacteria. if anaerobic organisms are suspected as accompanying aetiological agents, additional therapy should be considered.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - codeine phosphate hemihydrate, quantity: 30 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate - aspen codeine tablets are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fluconazole, quantity: 200 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - fluconazole injection is indicated for the following conditions but should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.

Bandaríkin - enska - NLM (National Library of Medicine)

aspen veterinary resources - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - flunixin meglumine 50 mg in 1 ml - horse: vetameg® 50 mg/ml is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. it is also recommended for the alleviation of visceral pain associated with colic in the horse. cattle: vetameg® 50 mg/ml is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. vetameg® 50 mg/ml is also indicated for the control of inflammation in endotoxemia. horse: there are no known contra-indications to this drug when used as directed. intra-arterial injection should be avoided. horses inadvertently injected intra-arterially can show adverse reactions. signs can be ataxia, incoordination, hyperventilation, hysteria and muscle weakness. signs are transient and disappear without antidotal medication within a few minutes. do not use in horses showing hypersensitivity to flunixin meglumine. cattle: nsaids inhibit production of prostaglandins which are important in signaling the initiation of partu

Bandaríkin - enska - NLM (National Library of Medicine)

aspen veterinary resources - oxytetracycline (unii: x20i9en955) (oxytetracycline anhydrous - unii:slf0d9077s) - oxytetracycline 200 mg in 1 ml - terra-vet® 200 is intended for use in the treatment of the following diseases in beef cattle; dairy cattle; calves, including preruminating (veal) calves; and swine when due to oxytetracycline-susceptible organisms: cattle: terra-vet® 200 is indicated in the treatment of pneumonia and shipping fever complex associated with pasteurella spp. and haemophilus spp.; infectious bovine keratoconjunctivitis (pink eye) caused by moraxella bovis; foot rot and diphtheria caused by fusobacterium necrophorum; bacterial enteritis (scours) caused by escherichia coli; wooden tongue caused by actinobacillus lignieresii; leptospirosis caused by leptospira pomona; and wound infections and acute metritis caused by strains of staphylococci and streptococci organisms sensitive to oxytetracycline. swine: terra-vet® 200 is indicated in the treatment of bacterial enteritis (scours, colibacillosis) caused by escherichia coli; pneumonia caused by pasteurella multocida; and leptospirosis caused by leptospira pomona. in

Bandaríkin - enska - NLM (National Library of Medicine)

aspen veterinary resources - penicillin g procaine (unii: 17r794esyn) (penicillin g - unii:q42t66vg0c) - penicillin g procaine 300000 [usp'u] in 1 ml - bactracillin g is indicated for treatment of bacterial pneumonia (shipping fever) caused by pasteurella multocida in cattle and sheep, erysipelas caused by erysipelothrix rhusiopathiae in swine, and strangles caused by streptococcus equi in horses.

Bandaríkin - enska - NLM (National Library of Medicine)

aspen veterinary resources - oxytetracycline hydrochloride (unii: 4u7k4n52zm) (oxytetracycline anhydrous - unii:slf0d9077s) - oxytetracycline anhydrous 100 mg in 1 ml - a great many of the pathogens involved in cattle diseases are known to be susceptible to oxytetracycline hydrochloride therapy. many strains of organisms, however, have shown resistance to oxytetracycline. in the case of certain coliforms, streptococci and staphylococci, it may be advisable to conduct culture and sensitivity testing to determine susceptibility of the infecting organism to oxytetracycline. in this manner, the likelihood of successful treatment with terra-vet™ 100 solution can be determined in advance.

Bandaríkin - enska - NLM (National Library of Medicine)

aspen veterinary resources - penicillin g procaine (unii: 17r794esyn) (penicillin g - unii:q42t66vg0c) - penicillin g 300000 [usp'u] in 1 ml - indications:  pen-aqueous® is indicated for the treatment of: 1. cattle and sheep - bacterial pneumonia (shipping fever) caused by pasteurella multocida. 2. swine - erysipelas caused by erysipelothrix rhusiopathiae. 2. horses - strangles caused by streptococcus equi.